INTRODUCTION
The primary treatment for advanced head and neck tumor is an approach combining surgery, radiation therapy and chemotherapy. Although such multimodality treatment has significantly improved tumor control and survival rate, [1] [2] [3] some clinical difficulties remain for: [1] tumors associated with locoregional disease failure 4) and second primary tumors; [2] tumors adjacent to critical structures, such as visual organs, cranial nerve and brain stem; [3] patients who cannot tolerate conventional aggressive therapy due to their age or poor general condition. 5) New approaches for these challenging tumors are thus clearly needed.
Technical development has made reproducible patient positioning and image-guided delivery of radiation possible, and stereotactic body radiation therapy (SBRT) has come to be adopted as an effective treatment for extracranial lesions. This technique involves the precise delivery of high dose radiation stereotactically to a target in a small number of fractions and the steep dose fall-off minimizes dose to surrounding tissues beyond a few millimeters. Some reports suggested that SBRT was available for selected patients with head and neck tumors when other conventional treatment options were not deemed to be feasible options. 6, 7) This therapy can be implemented with the CyberKnife Radiotherapy System (Accuray, Sunnyvale, CA), which is a nearly real-time image guided stereotactic radiotherapy system. 8, 9) The system includes a small 6 MV LINAC mounted on a robotic arm (for the administration of radiation), two diagnostic X-ray sources (installed in the ceiling of the treatment room) attached to digital image collectors placed orthogonally to the patient to provide nearly real-time treatment guidance.
10) The diagnostic X-ray sources coupled to the X-ray image detectors determine the position of the LINAC without the need for a stereotactic frame. A series of internal radiographic reference points, obtained from the bone structure or radio-opaque markers implanted close to the lesion, makes the localization of the target possible. This integrated imaging and delivery system has been used to treat extracranial diseases such as lung tumors, pancreas cancers, prostate cancers and head and neck tumors. 6, [11] [12] [13] [14] Although there have been few reports regarding CyberKnife SBRT for head and neck tumors, this study provides a retrospective review of the efficacy of CyberKnife SBRT for a selected group of patients with head and neck tumors.
METHODS

Patient characteristics
We retrospectively reviewed the medical records of fortyone consecutive patients with head and neck tumors who were treated with CyberKnife SBRT at Soseikai General Hospital between April 2005 and April 2008. Seven patients were excluded from this study because of presence of another cancer (hepatocellular carcinoma or lung cancer) (n = 3), unexpected early death secondary to other causes before response evaluation (n = 2) and lack of follow-up (n = 2). As a result, 34 patients were analyzed.
CyberKnife SBRT was offered as the sole treatment modality to a select group of patients after careful considerations when other treatment options, that is, surgery, conventional radiotherapy or chemotherapy were not deemed to be feasible. Treatment aim and possible complications were thoroughly discussed with patients and informed consent was obtained before treatment. Table 1 shows the characteristics of patients and tumors. The patients consisted of 22 male and 12 female, with the median age of 66 years (range, 48-86 years). Twenty-one patients had previously received radiotherapy with the median total dose for the initial therapy of 60 Gy (range, 50-70 Gy). The median interval between the initial radiation and re-irradiation was 51 months (range, 2-360 months). Fifteen of these patients were treated with SBRT for recurrences at the primary sites, five for recurrences in neck nodes and one for a second primary tumor. Of the 13 patients without prior radiotherapy, seven had tumors adjacent to visual organs, five were of advanced age (≥ 80 y.o.) and one was in poor general condition. The predominant histological type was squamous cell carcinoma (n = 20) and the others were adenocarcinoma (n = 3), melanoma (n = 3), adenoid cystic carcinoma (n = 2), lymphoma (n = 2), undifferentiated carcinoma (n = 2), small cell carcinoma (n = 1) and leiomyosarcoma (n = 1).
Treatment procedure
The CyberKnife SBRT procedure consists of three steps: [1] Simulation CT image acquisition based on skull-bone landmarks, [2] treatment planning and [3] treatment delivery.
First, a customized thermoplastic mask was used to minimize patient movement on the day of the simulation CT scan. Simulation CT with intravenous contrast was then obtained with a 1.25-mm slice thickness in a standard manner from the top of the skull to the thoracic inlet. The images were transferred to the CyberKnife treatment planning system for the patient's contour and anatomical information.
For the second step of CyberKnife SBRT, treatment planning, an individualized treatment plan was developed for each patient according to the clinical and radiographic findings. The target volume and organ at risk were defined based on simulation CT images fused with magnetic resonance Abbreviation: RT = radiotherapy.
imaging. The gross tumor volume (GTV) was defined as the visible tumor in the imaging studies. If internal physiological variations such as respiration and swallowing movements were anticipated, the contour was slightly overdrawn especially in the superior-inferior direction and was defined as the internal target volume (ITV). No additional margin was added for the planning target volume (i.e., GTV or ITV = PTV). Inverse planning computer algorithm determined the number, direction and duration of treatment beams. Patients were treated with the median dose of 30 Gy (range, 19.5-42 Gy) in the median of 5 fractions (range, 3-8 fractions) prescribed to 90% of the PTV (D90). The median dose of 30 Gy in 5 fractions prescribed to D90 was the most frequent regimen (n = 13) employed in this series. The median target volume was 11.6 cm 3 (range, 0.7-78.1 cm 3 ). The total dose and fractional dose were determined individually according to the tumor volume, prior radiotherapy and interval until current re-irradiation, and the patient's general condition. No patients received chemotherapy concurrently with CyberKnife SBRT. The median treatment duration was 5 days (range, 3-9 days).
The biological effective dose (BED) was calculated based on the linear quadratic model using the α/β ratio of 10 Gy for antitumor effects and based on D90 and D100. Although one of the limitations of using BED formulation is lack of the experimental validity for large doses per fraction and short overall treatment duration, it currently serves as a useful model for biological comparison of different fractionations. The percent volume obtaining 100%, 110% and 95% of the prescribed dose was also calculated (V100, V105, V95).
The third step of CyberKnife SBRT is the actual treatment delivery. During treatment, two orthogonally positioned diagnostic X-ray cameras provided nearly real-time images of the patient's internal anatomy. Skull tracking was used to determine the tumor location. Treatment duration ranged from 30 to 90 min per fraction, depending on the dose per fraction, the number of beam nodes and patient's compliance. The treatment was performed on consecutive days except Sundays. Table 2 summarized the treatment parameters.
Toxicity evaluation
To minimize bias and inaccuracy for retrospective grading of morbidity, we rated toxicity on a three-point scale: absent, minor-to-moderate or severe. The last was assigned if the patient was hospitalized, required surgical intervention or died as a result of treatment (almost equivalent to toxicity grade 4 or 5 of the Common Terminology Criteria for Adverse Events (CTCAE) v3.0). Cumulative BED with the ratio of 2 Gy was calculated for late toxicity by using the prior irradiation dose and CyberKnife prescription dose (D90).
Statistical analysis
All statistical analyses were performed using StatView 5.0 software. Overall survival (OS) was estimated using the Kaplan-Meier method. The Fisher's exact test and the logrank test were used to detect statistical differences in OS and overall response rate (CR + PR), respectively, between strata of selected variables. The variables included were gender, age, prior radiotherapy, re-irradiation interval, disease site, histological type, target volume and radiation intensity (using BED10-D90 and BED10-D100).
RESULTS
Treatment results
The median follow-up time after CyberKnife SBRT was 16 months (range, 3-51 months). Locoregional response rates were determined on the basis of radiographic and clinical assessment (Table 3) . Overall, complete response rate and partial response rate were 32% and 38%. None of the variables showed any significant correlation with better The overall survival rates for the 34 patients were 70.6% and 58.3% at 12 and 24 months, respectively (Fig. 1) , and the median survival time was 28 months. The factors associated with better overall survival were the absence of prior radiotherapy within the previous 24 months and smaller target volume (< 15cm
3 ) (Fig. 2) . Nine (27%) patients who had undergone prior radiotherapy within the previous 24 months were all treated for recurrent tumors. Of this cohort, 6 patients died of tumor progression and 1 died of brain hemorrhage. Only one patient is surviving without tumor progression. The other variables showed no significant correlation with better overall survival.
Complications
All patients completed the CyberKnife SBRT schedule. The patients were hospitalized to be prepared for unforeseeable circumstances but none of them suffered any severe acute complications during the treatment period. However, severe late complications occurred in 6 patients, all of who were in the re-irradiation group, with the median time to development of 5 months after CyberKnife SBRT (Table 4) . Two patients developed massive hemorrhage in the pharynx and died of this complication 5 and 28 months, respectively, after CyberKnife SBRT. Two patients suffered from severe mucositis and dysphagia to require hospitalization for direct intervention and symptomatic management. Necrosis of the skin in the re-irradiation area was observed in one patient. Biopsies of patients No. 1 and 3 (Table 4 ) produced a negative diagnosis. There were no statistically significant correlations between severe complications and prior radiotherapy, target volume or cumulative BED 2 . Figure 3 illustrates the case of a patient who had recurrent tongue cancer in a right submandibular lymph node and was treated by re-irradiation with CyberKnife SBRT. After 18 months of treatment, tissue necrosis and pharyngocutaneous fistula were observed very close to the right carotid artery. Although the patient was pathologically diagnosed negative and managed conservatively, the necrotizing area gradually Abbreviations: RT = radiotherapy; CK SBRT = CyberKnife stereotactic body radiation therapy; BED = biological effective dose; TV = target volume; LNs = lymph nodes 
DISCUSSION
This study deals with the use of CyberKnife SBRT for patients with head and neck tumors and divided into an irradiated and an unirradiated cohort. The former cohort consisted of patients with locoregional recurrence or second primary tumor in the prior irradiation area. Despite major advances in the treatment of head and neck tumors, locoregional recurrence remains a significant problem since nearly 50-60% of such patients will die because of recurrent locoregional disease [15] [16] [17] and secondary tumors (which occur in up to 40% of successfully treated patients).
18) Salvage treatment for these patients is usually difficult because of deep-seated location, proximity to a critical structure and high radiation dose received during primary treatment. Surgical salvage is sometimes successful but is not always feasible because of disease extent or involvement of critical structures. Traditionally, many inoperable patients have been referred for palliative chemotherapy, however, chemotherapy alone yields at most 40% response rate. 19, 20) Moreover, these responses are usually transient with median survival limited to 6-9 months.
Therefore, several authors studied about high-dose radiation therapy as one of alternatives. Choy et al. reported on their experience with brachytherapy for residual or recurrent nasopharyngeal carcinoma.
21) The local tumor control was achieved for 60% to 80% of their patients, a relatively satisfactory result. Simultaneously procedure-related morbidities such as headache, fistula of soft palate and necrosis of nasopharynx mucosa also occurred. Brachytherapy should be considered in cases of oral, oropharyngeal and nasopharyngeal tumors if surgery is not feasible. However, brachytherapy re-irradiation requires general anesthesia and an invasive procedure in already compromised tissues. Thus, brachytherapy may be limited to patients with superficial and minor recurrence for which gamma rays from radioactive sources can be effective. It should not be used for more extensive recurrences involving deep-located tissues and skull base.
Recently, SBRT and intensity-modulated radiation therapy (IMRT) have been receiving special attention as new radiotherapy methods which permit extremely conformal delivery of definitive doses while sparing neighboring normal tissues. These new radiation technologies, therefore, look promising for the treatment of head and neck tumors in prior irradiation areas.
Wu et al. reported on their experience using SBRT for salvage of local failure in 90 patients with persistent or recurrent nasopharyngeal cancer. 22) The median dose was either 18 Gy in three fractions for persistent group or 48 Gy in six fractions for recurrent group. Complete response rate after SBRT was 66% for persistent group and 63% for recurrent group. Disease-specific survival and progression-free survival rates for all patients after 1, 2 and 3 years were 82.6%, 74.8%, 57.5% and 72.9%, 60.4%, 54.5%, respectively. Sulman et al. reported a result for re-irradiation with IMRT for 74 patients with head and neck cancer.
23) The median reirradiation dose was 60 Gy and the median cumulative radiation dose was 116.1 Gy. Seventy-three patients (99%) were treated with 2 Gy daily fractions. The 2-year overall survival and locoregional control rates were 58% and 64%, respectively. In these cases, too, the use of SBRT and IMRT for reirradiation of recurrent or second primary head and neck tumors resulted in encouraging local control and survival.
Our preliminary data also supports the effectiveness of reirradiation with CyberKnife SBRT for the treatment of head and neck tumors. The overall response rate for our patients was 61.9% and the 2-year overall survival rate was 50%.
There is no prospective or retrospective data for a comparison of re-irradiation using conventional fractionation IMRT with SBRT. In terms of treatment duration, however, SBRT has a clear advantage over conventional fractionation IMRT. The former can be usually completed in about one week without severe acute complications. The latter usually needs six weeks or more and sometimes causes severe acute toxicity and resultant treatment breaks. 24) Patients requiring re-irradiation have already received definitive treatment and cannot often tolerate prolonged high-intensity therapy. In our study, all patients could complete their therapeutic course as planned, without intermission or severe acute toxicity. Treatment in relatively short duration without severe acute complications thus constitutes an important advantage of SBRT which conventional fractionated radiation therapies, including IMRT, do not have.
In this study, CyberKnife SBRT was also used for head and neck tumors not previously treated with radiation therapy. Some recent reports 6, 25, 26) have suggested that SBRT was effective as a definitive therapy for selected patients who had primary tumors in the head and neck region and were not eligible for other treatment options, and also as an effective palliative modality for patients with metastatic tumors in this area. Although careful consideration of its indication is essential, SBRT may become a useful therapeutic tool when other treatment options are not deemed to be feasible because of poor general condition, advanced age and significant medical comorbidity. We also successfully controlled local tumor progression, except for one case with cervical lymph node metastasis of anaplastic thyroid carcinoma, and observed no severe complication. Patients in this cohort were generally in poor conditions and also could reap the benefits of the short duration and safety of SBRT.
The prognostic importance of tumor volume for SBRT observed in our study was consistent with the findings reported in the literature. Wu et al. found that larger tumor volume (≥ 5cc) resulted in both poorer disease-specific sur-vival and progression-free survival. 23) They presumed the reason for this finding was higher risk of distant failure for the larger tumor group and speculated that additional chemotherapy might improve survival. Prior radiotherapy within the previous 24 months also resulted in poorer overall survival in our study. This cohort consisted of patients with relatively early recurring tumors and might have more highgrade tumors. It seems that such uncontrollable tumors need chemotherapy in addition to re-irradiation. Heron et al. have initiated a Phase II clinical trial of concurrent administration of cetuximab and SBRT. 14) Because of the high cumulative doses of radiation, the possibility of chronic toxicities by re-irradiation should not be overlooked. Up to 30% of occurrence rates of late complications due to re-irradiation have been reported, ranging from mild trismus or neck fibrosis to severe complications such as fatal carotid hemorrhage. [27] [28] [29] [30] In our series, we observed severe late complications in 18% of the patients and 2 patients died of carotid hemorrhage. The number of patients was too small for a statistically robust determination of risk factors, but the fact that severe late complications were found only in patients with prior radiotherapy suggests that such treatment constitutes a risk factor. Although it is hoped that treatment-induced morbidity is minimized by the use of SBRT and limiting the target to gross disease, the radiation dose for the tumor itself and tissue surrounding it within a few millimeters cannot be reduced. No matter how small re-irradiation area is, we should not be careless about necrotization of that area.
Carotid hemorrhage has often been reported as a fatal adverse event, [28] [29] [30] since it often becomes difficult to manage once this side-effect develops. In our experience with 2 of the patients, pressure hemostasis and arterial embolization were tried for massive hemorrhage from the re-irradiated area, and temporary hemostasis was achieved. Somewhat later, however, both patients died of rebleeding. In cases the tumor is closely situated to or invades the carotid artery in the prior irradiation area, careful attention should be paid to occurrence of this complication.
Our study had several important limitations. [1] It is based on a non-randomized heterogeneous cohort of patients from a single institution. Therefore, no definitive causal inferences should be drawn from our findings. [2] Because toxicities were retrospectively determined based on chart reviews rather than prospectively collected, it is possible that not all complications were noted. [3] Our median follow-up of 16 months was not enough to fully assess the long-term complications led by re-irradiation.
However, it is clear this technique offers definite advantages over conventional fractionated radiation therapy. The practical advantage is that the treatment generally takes only about one week. Although more clinical experiences and longer follow-up are needed to validate our results, we believe SBRT for head and neck tumors will evolve as a result of more extensive experience and thus merits further study. In conclusion, our preliminary results suggest that SBRT is effective for head and neck tumors and has the advantage of short treatment duration. However, late complications comprising necrosis and hemorrhage in re-irradiated areas warrant special caution.
